Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-Week Prospective, Open-Label, Multicenter Study to Evaluate the Effect on Seizure Frequency, Safety and Tolerability of Oxcarbazepine Monotherapy in Adult Patients With Partial Seizures

NCT00275925 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00275925
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00275925 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-Week Prospective, Open-Label, Multicenter Study to Evaluate the Effect on Seizure Frequency, Safety and Tolerability of Oxcarbazepine Monotherapy in Adult Patients With Partial Seizures
Lead sponsor
Novartis
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2005
Completion date
March 31, 2007
Enrollment
80
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy, partial seizures